Identification of key biomarkers for STAD using filter feature selection approaches

Yangyang Wang¹,², Jihan Wang², Ya Hu³, Jingbo Shangguan⁴, Qiyong Song⁴, Jing Xu⁴, Hanping Wang⁵, Mengju Xue⁴, Liping Wang⁶ & Yuanyuan Zhang⁶

Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer death worldwide. Discovery of diagnostic biomarkers prompts the early detection of GC. In this study, we used limma method combined with joint mutual information (JMI), a machine learning algorithm, to identify a signature of 11 genes that performed well in distinguishing tumor and normal samples in a stomach adenocarcinoma cohort. Other two GC datasets were used to validate the classifying performances. Several of the candidate genes were correlated with GC tumor progression and survival. Overall, we highlight the application of feature selection approaches in the analysis of high-dimensional biological data, which will improve study accuracies and reduce workloads for the researchers when identifying potential tumor biomarkers.

Stomach cancer, or gastric cancer (GC), is the fifth most diagnosed cancer and the third leading cause of cancer death worldwide. The most common type of GC is stomach adenocarcinoma (STAD), which accounts for almost 90% of all GC cases. Because the symptoms of GC can be mistaken for less serious problems like indigestion or heartburn, it is frequently misdiagnosed until the advanced stages. The outcome of GC treatment is generally poor, with a 5-year survival rate of nearly 30%.

The non-invasive and low-cost advantages of diagnostic biomarkers prompt the researches of molecular biomarkers for the early detection of gastric cancer. However, the challenges in identifying promising biomarkers with exceptional discriminative performance are increasing. As high-throughput technologies and machine learning methods advance, feature selection approaches for classification are being applied to cancer genomic studies. The Cancer Genome Atlas (TCGA, https://www.cancer.gov/tcga) database, which includes 33 cancer types and over 20,000 primary cancer samples as well as massive gene expression data, has become one of the most widely used databases for cancer research. In addition, the Genotype-Tissue Expression (GTEx, http://commonfund.nih.gov/GTEx) database establishes a reference resource of gene expression from 'normal' or disease-free tissues, which balances the sample size between tumor and normal groups and enlarges the samples when performing machine learning methods. In general, there are tens of thousands of genes and far fewer samples than the number of genes in high-throughput sequencing data, forcing researchers to obtain appropriate biomarkers using machine learning heuristic algorithms. Feature selection has been used as a promising method to discover subsets of molecular markers that identify target classes of clinical cases. The advantages of feature selection applied to high-throughput sequencing data are mainly manifested in two aspects: (1) the reduction of complexity through the elimination of relatively unimportant or redundant features, and (2) the improvement of classification accuracy and efficiency.

More efficient and robust feature selection methods are required to identify a small set of genes in order to improve classification performances. In this study, we combined two filter feature selection methods, limma and JMI algorithms, to identify key gene signatures for GC tumor and normal tissue discrimination. Specifically, we recruited the STAD cohort from the TCGA database as a test dataset, and two other GC datasets from NCBI-GEO DataSets were chosen as validation datasets. The expression alterations of the selected genes and
clustering performance based on the selected genes were investigated. Besides, the biological application of the candidate genes were also analyzed.

**Materials and methods**

**Data acquisition.** As the testing dataset, STAD expression profiling was extracted from the total RSEM expected_count dataset (https://toil-xena-hub.s3.us-east-1.amazonaws.com/download/TCGA-GTEx-TARGET-gene-exp-counts.deseq2-normalized.log2.gz), which combines the cohort of TCGA, TARGET, and GTEx samples and can be downloaded from the UCSC xena website. The STAD dataset included 413 tumor samples (all from the TCGA database) and 210 normal samples (36 from the TCGA and 174 from the GTEx). For biological, the TCGA-STAD cohort’s survival dataset (https://gdc-hub.s3.us-east-1.amazonaws.com/download/TCGA-STAD.survival.tsv) and phenotype dataset (https://gdc-hub.s3.us-east-1.amazonaws.com/download/TCGA-STAD.GDC_phenotype.tsv.gz) were also acquired. Table 1 summarizes the clinicopathological characteristics of the 413 STAD tumor samples.

| Group          | Number |
|----------------|--------|
| Age (year)     |        |
| <65 (year)     | 167    |
| ≥65 (year)     | 214    |
| Not reported   | 3      |
| No information | 29     |
| Gender         |        |
| Female         | 133    |
| Male           | 251    |
| No information | 29     |
| Race           |        |
| Asian          | 84     |
| Black          | 12     |
| White          | 241    |
| Not reported   | 47     |
| No information | 29     |
| Tumor stage    |        |
| Stage I        | 51     |
| Stage II       | 120    |
| Stage III      | 162    |
| Stage IV       | 37     |
| Not reported   | 14     |
| No information | 29     |
| OS (overall survival) status | |
| Alive          | 225    |
| Dead           | 159    |
| No information | 29     |
| OS (overall survival) time (days) | |
| Alive          | 724.42 ± 585.39 |
| Dead           | 439.06 ± 374.52 |
| Total number   | 413    |

Table 1. Clinical characteristics of STAD cases.
most relevant features from all features in order to reduce complexity of high-dimensional classification problems, has become the mainstream method\textsuperscript{12}. The information gain (IG) method considers only the correlation between each sub-feature and the target classification separately, without taking into account the relationship between features. According to the principle of maximum dependency, maximum correlation and minimum redundancy based on mutual information, Peng et al. proposed the minimum redundancy Maximum relevance (mRMR) framework\textsuperscript{13}, which has been applied for feature selection in many fields, including biological data. Equation 1 depicts the expression of the mRMR algorithm. Furthermore, the JMI algorithm\textsuperscript{14,15} provided a more comprehensive and widely used feature selection framework by taking mutual information between subset features and unselected features into account under IG-based classification conditions. The JMI algorithm was expressed as Eq. 2. Instead of focusing on the direct relationship in the mRMR framework, the JMI algorithm considers all mutual information between features, including the indirect correlation. In view of these, we used the JMI algorithm for feature selection based on the DEGs obtained from limma.

\begin{equation}
\alpha(f_i) = I(f_i; C) - \frac{1}{|S|} \sum_{f_s \in S} I(f_i; f_s) \tag{1}
\end{equation}

\begin{equation}
\alpha(f_i) = \sum_{f_s \in S} I(f_i; f_s; C) \tag{2}
\end{equation}

In the above two equations, \( F \), \( S \) and \( C \) represent the total features, the selected features and the classification, respectively; while \( f_s \) and \( f_i \) mean the features belonging to \( S \) and \( F \backslash S \). \( I(f_i, f_s) \) is the mutual information between \( f_i \) and \( f_s \), and \( I(f_i, f_s; C) \) is the mutual information between \( f_s \), \( f_i \) and \( C \). For the equation of \( I(f_i, f_s) \), the larger the value of \( I \), the stronger the correlation between \( f_i \) and \( f_s \).

In this study, we used both the two filter algorithms of limma and JMI as the hybrid method, to obtain key biomarkers for classifying tumor and normal tissues in gastric cancer. By this way, we could use as few gene features as possible to achieve better classification performances.
Validation of the selected gene signatures with GEO datasets. After running the limma and JMI algorithms sequentially, we will obtain the candidate gene features for classifying tumor and normal samples in STAD cohort. We then validated the candidate genes in other two gastric cancer cohorts, including GSE33335 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33335)\(^{16,17}\) and GSE103236 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103236)\(^{18,19}\) from the NCBI-Gene Expression Omnibus (GEO) DataSets. The GSE33335 dataset contains gene expression profiling of 25 pairs of gastric tissues: gastric cancer tissues vs. matched adjacent noncancerous tissues. The GSE103236 dataset contains gene expression profiling of gastric adenocarcinoma (10 samples) and normal adjacent tissues (9 samples).

Bioinformatic and biological analysis. T-SNE and heatmap analysis: The algorithms of t-distributed stochastic neighbor embedding (t-SNE)\(^ {20}\) and bi-clustering analysis were performed in R using the “Rtsne” and “pheatmap” packages, respectively, to illustrate the distribution of GC tumor and normal samples based on the previously selected genes.

ROC analysis of candidate genes: To evaluate the diagnostic performance of candidate genes, we examined the specificity, sensitivity, and area under the curve (AUC) values obtained by using receiver operator characteristic (ROC) analysis in MedCalc software.

Identifying candidate genes associated with tumor stage and patient survival: The phenotype information including tumor stage and the survival information for STAD patients were derived from the TCGA database. Tumors are classified into four stages based on their stage status: I, II, III, and IV. We considered these genes to be stage-related biomarkers after discovering that changes in average gene expression were consistent with tumor stage progression. We used the R package “Survminer” to analyze and visualize the Kaplan–Meier curves of candidate genes based on their expression profiling for survival analysis.

Results

A set of 11 genes was identified as biomarkers to differentiate STAD tumor samples from normal samples. The original STAD dataset contains 60,499 gene identifiers profiles. After data preprocessing, we obtained expression profiles of 58,581 unique genes for each of the 623 samples. The “limma” algorithm was then used to initially selected the DEGs that differed between STAD tumor and normal samples. A total of 8,863 DEGs were screened using the criterion of log|FC|> 1 and adj.P < 0.05 between the two groups. The JMI algorithm was then used to obtain the optimal combination of gene features with maximum classification performance and minimum redundancy. Finally, a set of 11 genes were identified as candidate biomarkers for differentiating between tumor and normal groups among the 8863 DEGs, including STX12, PHF14, ECT2, PRIM2, CENPL, CTHRC1, INHBA, RNFT2, CLSPN, ESM1, and COL10A1. Only STX12 was down-regulated in tumors, while the other ten DEGs were all significantly up-regulated in tumors compared to the normal samples, as shown in Fig. 2.

Performances of the 11 candidate genes in classifying tumor and normal groups. In this study, we performed t-SNE and bi-clustering heatmap to show the classification of STAD tumor and normal samples based on the DEGs profiling. Firstly, the t-SNE and heatmap visualization based on the 8,863 DEGs obtained from limma algorithm revealed a relatively distinct distribution between the two groups (Figs. 3A, S1). Further, after using the JMI method, we observed a more desirable discrimination model based on profiling of the 11 selected genes, with only four (4/413) tumor samples distributed concordantly into the normal group in both t-SNE and heatmap analysis (Fig. 3B,C). The results indicated that the combination of limma approach and JMI algorithm improved the accuracy and efficiency in classifying different groups. Finally, the ROC analysis
revealed generally excellent results when the selected genes were used as diagnostic biomarkers. Specifically, the AUCs of the ten up-regulated genes in tumors ranged from 0.983 to 0.990, whereas the diagnostic performance of the down-regulated gene STX12 in tumors was less than optimal, with AUC = 0.615, as shown in Fig. S2A.

Validation of the 11 selected gene signatures in two GEO datasets. As described in the method, we chose two datasets of gastric cancer from the GEO databases to confirm the expression pattern and classifying performance of the previously selected 11 genes. In the GSE33335 dataset, we found a consistent expression pattern, in which the expression of ten of the 11 genes increased while the expression of STX12 decreased in tumor compared to normal tissues (P < 0.001 in two-tailed paired-sample t test, Fig. S3A). In the GSE103236 dataset, the expression profiling contains about 45,000 gene IDs, while the expression information of gene RNFT2 was not included in the total gene expression profiling. Therefore, we analyzed the remaining ten candidate genes in this dataset. In general, the expression patterns of these ten genes were almost identical to the previous results, with the exception that CLSPN expression was slightly lower in tumor tissues than in normal tissues, but this difference was not statistically significant (P = 0.81). Similarly, STX12 expression was significantly reduced while the expression of the other eight genes increased in tumor tissues (P < 0.05 in two-tailed t test, Fig. S3B). We then investigated the classifying abilities of the selected gene signatures in the two datasets. As shown in Fig. 4, t-SNE visualizations and heatmaps based on the gene signatures produced satisfactory discrimination clusters between tumor and normal groups. The AUCs of these 11 genes ranged from 0.806 to 0.979 in the GSE33335 dataset. The performance of gene CLSPN in the GSE103236 dataset was poor, with AUC = 0.528; and AUCs of the other nine genes ranged from 0.789 to 1.000. Taken together, these findings support the promising application of feature selection approaches in the processing of high-throughput biological data.

Figure 3. Classification of STAD tumor and normal groups. (A, B) T-SNE plots displayed the distribution of tumor and normal samples based on the 8,863 DEGs and the 11 candidate genes, respectively. (C) Bi-clustering heatmap of the 11 candidate genes and all 623 samples. DEGs: differentially expressed genes.
Figure 4. Classification between gastric tumor and normal tissues. (A) T-SNE plots displayed the distribution of tumor and normal samples based on the 11 candidate genes in the GSE33335 dataset. (B) T-SNE plots displayed the distribution of tumor and normal samples based on the ten candidate genes in the GSE103236 dataset. (C) Bi-clustering heatmap of the 11 candidate genes and 50 samples in the GSE33335 dataset. (D) Bi-clustering heatmap of the ten candidate genes and 19 samples in the GSE103236 dataset.
Next, we investigated whether the expression profiles of the candidate genes could reflect tumor progression or predict the prognosis. Table S1 summarized the relative gene expression of the 11 candidate genes in four subgroups according to tumor stage. Specifically, in the ten up-regulated genes, we discovered that the relative expression levels of two genes, ECT2 and RNFT2, gradually increased with the progression of stage status, as shown in Fig. 5. The average values of ECT2 in four subgroups were 12.10, 12.16, 12.27, 12.40, respectively; and the average values of RNFT2 in four subgroups were 8.36, 8.57, 8.58, 8.59, respectively. Despite the fact that gene expression levels were only moderately or slightly different among the four subgroups, the results demonstrated that these two genes may have the potential to reflect tumor progression to some extent.

The overall survival (OS) Kaplan–Meier plot also revealed significantly different prognostic outcomes based on gene expression level. Higher levels of genes including COL10A1, CTHRC1, and INHBA were associated with poor survival probabilities in STAD patients ($P < 0.01$, Fig. 6).

**Figure 5.** Relative expression levels of ECT2 and RNFT2 in tumor subgroups at various stages. The violin boxplots depicted value ranges of the two genes, with the dot in each plot representing the average value.

**Figure 6.** Kaplan–Meier survival curves based on COL10A1, CTHRC1, and INHBA expression levels. The cut-off values classified gene expression as high (high) or low (low). The horizontal axis represents survival time (days), and the vertical axis represents overall survival rate.

### Identifying gene biomarkers associated with stage and survival in STAD tumors

Next, we investigated whether the expression profiles of the candidate genes could reflect tumor progression or predict the prognosis. Table S1 summarized the relative gene expression of the 11 candidate genes in four subgroups according to tumor stage. Specifically, in the ten up-regulated genes, ECT2 and RNFT2, gradually increased with the progression of stage status, as shown in Fig. 5. The average values of ECT2 in four subgroups were 12.10, 12.16, 12.27, 12.40, respectively; and the average values of RNFT2 in four subgroups were 8.36, 8.57, 8.58, 8.59, respectively. Despite the fact that gene expression levels were only moderately or slightly different among the four subgroups, the results demonstrated that these two genes may have the potential to reflect tumor progression to some extent.

The overall survival (OS) Kaplan–Meier plot also revealed significantly different prognostic outcomes based on gene expression level. Higher levels of genes including COL10A1, CTHRC1, and INHBA were associated with poor survival probabilities in STAD patients ($P < 0.01$, Fig. 6).

### Discussion

While the development and generation of high-throughput technologies and omics data have improved our understanding complex biological characteristics such as tumors, brains, and developmental systems, they have also created significant technical challenges during the analysis. Typically, researchers identify differentially expressed/abundant molecules (genes, proteins, or metabolites) between tumor and control groups as preliminary results for biomarker analysis. We must accept the fact that hundreds or even thousands of DEGs between two groups were always detected in the high-dimensional gene expression datasets. As a result, in addition to traditional methods, more approaches are required to efficiently and accurately select the key gene signatures that could classify the disease between normal samples$^{21,22}$. In this study, we combined two approaches, limma and JMI algorithms, and finally identified a set of 11 genes with powerful discrimination effects between STAD tumor and normal tissues. Remarkably, additional independent validation with two GC datasets confirmed the expressed alterations as well as the classifying performance of the chosen gene sets.

Some candidate genes have been linked to gastric cancer. COL10A1, a member of the collagen family and the main matrix component, is high expressed in gastric cancer compared to the normal tissues and an independent predictor of poor overall survival$^{23}$. On the mechanism, COL10A1 was confirmed to be a potential inducer.
of epithelial-to-mesenchymal transition (EMT) and could regulate the migration and invasion of GC cells.\textsuperscript{24} CTHRC1 is known to be involved in tissue remodeling processes and closely associated with carcinogenesis and metastasis in solid tumors.\textsuperscript{25} CTHRC1 has been shown to prompt gastric cancer metastasis via HIF-1α/CXCR4 signaling pathway\textsuperscript{27}, and to be a common diagnostic and prognostic biomarker in six different human cancer subtypes, including STAD.\textsuperscript{26} Highly expression of INHBA and activation of TGF-β signaling pathways were observed in GC tissues, and INHBA gene silencing inhibited the GC progression by inactivating the TGF-β signaling pathway\textsuperscript{27}. INHBA may also be an optimally reliable biomarker for diagnosing GC and lymph-node (LN) metastasis\textsuperscript{28}. Consistent with the above reports, we discovered that the expressions of COL1A1, CTHRC1, and INHBA were significantly up-regulated in tumor tissues in the TCGA-STAD cohort and two GEO gastric cancer datasets. Furthermore, high expression levels of the three DEGs were associated with significantly poor survival probabilities in tumor patients ($P < 0.01$). Besides, we also discovered that the average expressions of two genes, ECT2 and RNFT2, increased concordantly with the tumor stage progression. Recent studies reported that upregulation of ECT2 predicted adverse clinical outcomes and increased 5-fluorouracil (5-Fu) resistance in GC patients\textsuperscript{29}, and was associated with transcriptional program of cancer stem cells (CSCs)\textsuperscript{30}. So far, studies on the roles of RNFT2 in cancer research is relatively rare. A recent study demonstrated that tissue RNFT2 expression levels are associated with peritoneal recurrence and poor prognosis in GC\textsuperscript{31}. Taken together, our results and other related findings suggest that the five upregulated genes mentioned above could be potential targets for GC research.

In contrast to the upregulated DEGs, we discovered that STX12 expression was significantly and consistently lower in tumor compared to normal tissues in all three GC cohorts. STX12 is a SNARE protein that mediates vesicle fusion at endosomes and functions as a new component of the α-granule biogenesis machinery.\textsuperscript{32} STX12 was upregulated through the ROS/STAT3/NFE2L1 axis in hepatoma cells, and it was a key downstream effector of NFE2L1 in modulating hepatoma cell invasiveness\textsuperscript{33}. So far, there has been no report on the roles of STX12 in gastric cancer, which may necessitate further studies.

**Conclusion**

In conclusion, our study identified a small set of genes (11 candidate genes including STX12, PHF14, ECT2, PRIM2, CENPL, CTHRC1, INHBA, RNFT2, CLSPN, ESM1, and COL10A1) that could be used to distinguish gastric cancer from normal tissues in TCGA cohort by using the combination feature selection methods of limma and JMI. Meanwhile, the classification performance of the candidate genes was further validated in other two gastric cancer cohorts in GEO datasets. Moreover, we explored that several candidate genes involved in gastric cancer progression and prognosis. We highlighted the application of machine learning, particularly feature selection approaches, in the analysis of high-dimensional biological data for discovering valuable biomarkers, which will improve accuracies and reduce workloads for the researchers when identifying potential biomarkers of tumors.

**Data availability**

The datasets analysed during the current study are available in the FigShare repository, https://figshare.com/articles/dataset/Gene_expression_data_in_gastric_cancer/19733347.

Received: 5 May 2022; Accepted: 30 September 2022
Published online: 18 November 2022

**References**

1. Collaborators, G. B. D. S. C. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: A systematic analysis for the Global Burden of Disease study 2017. *Lancet Gastroenterol. Hepatol.* 5, 42–54. https://doi.org/10.1016/S2468-1253(19)30328-0 (2020).
2. Zheng, L. et al. The survival and the long-term trends of patients with gastric cancer in Shanghai, China. *BMC Cancer* 14, 300. https://doi.org/10.1186/1471-2407-14-300 (2014).
3. Walk, E. E. et al. The cancer immunotherapy biomarker testing landscape. *Arch. Pathol. Lab. Med.* 144, 706–724. https://doi.org/10.5858/arpa.2018-0584-CP (2020).
4. Huang, S. et al. Applications of support vector machine (SVM) learning in cancer genomics. *Cancer Genomics Proteomics* 15, 41–51. https://doi.org/10.21873/cgp.20063 (2018).
5. Linehan, W. M. & Ricketts, C. J. The Cancer Genome Atlas of renal cell carcinoma: Findings and clinical implications. *Nat. Rev. Urol.* 16, 539–552. https://doi.org/10.1038/s41585-019-0211-5 (2019).
6. Tomczak, K., Czerwinska, P. & Winerowicz, M. The cancer genome atlas (TCGA): An immeasurable source of knowledge. *Contemp. Oncol. (Pol)* 19, A68-77. https://doi.org/10.5114/co.2014.47136 (2015).
7. Xiao, W., Wang, X., Wang, T. & Xing, J. Overexpression of BMP1 reflects poor prognosis in clear cell renal cell carcinoma. *Cancer Gene Ther.* 27, 330–340. https://doi.org/10.1038/s41417-019-0107-9 (2020).
8. Consortium, G. T. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* 348, 648–660. https://doi.org/10.1126/science.1262110 (2015).
9. Donovan, M. K. R., D’Antonio-Chronowoska, A., D’Antonio, M. & Frazer, K. A. Cellular deconvolution of GTEx tissue powers discovery of disease and cell-type associated regulatory variants. *Nat. Commun.* 11, 955. https://doi.org/10.1038/s41467-020-14561-0 (2020).
10. Torres, R. & Judson-Torres, R. L. Research techniques made simple: Feature selection for biomarker discovery. *J. Invest. Dermatol.* 139, 2068–2074. https://doi.org/10.1016/j.jid.2019.07.682 (2019).
11. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucl. Acids Res.* 43, e47. https://doi.org/10.1093/nar/gkv007 (2015).
12. Tsagris, M., Lagani, V. & Tsamardinos, I. Feature selection for high-dimensional temporal data. *BMC Bioinform.* 19, 17. https://doi.org/10.1186/s12859-018-2023-7 (2018).
13. Peng, H., Long, F. & Ding, C. Feature selection based on mutual information criteria of max-dependency, max-relevance, and min-redundancy. *IEEE Trans. Pattern Anal. Mach. Intell.* 27, 1226–1238 (2005).
14. Vergara, J. R. & Estévez, P. A. A review of feature selection methods based on mutual information. *Neural Comput. Appl.* 24, 175–186 (2014).
15. Bennasar, M., Hicks, Y. & Setchi, R. Feature selection using joint mutual information maximisation. Exp. Syst. Appl. 42, 8520–8532 (2015).
16. Cheng, L. et al. Global gene expression and functional network analysis of gastric cancer identify extended pathway maps and GPRCSA as a potential biomarker. Cancer Lett. 326, 105–113. https://doi.org/10.1016/j.canlet.2012.07.031 (2012).
17. Cheng, L. et al. A 4-gene panel as a marker at chromosome 8q in Asian gastric cancer patients. Genomics 102, 323–330. https://doi.org/10.1016/j.ygeno.2013.05.004 (2013).
18. Necula, L. et al. High plasma levels of COL10A1 are associated with advanced tumor stage in gastric cancer patients. World J. Gastroenterol. 26, 3024–3033. https://doi.org/10.3748/wjg.v26.i22.3024 (2020).
19. Chivu Economescu, M. et al. Identification of potential biomarkers for early and advanced gastric adenocarcinoma detection. Hepatogastroenterology 57, 1453–1464 (2010).
20. Van der Maaten, L. & Hinton, G. Visualizing high-dimensional data using t-SNE. J. Mach. Learn. Res. 9, 2579–2605 (2008).
21. Ang, J. C., Mirzal, A., Haron, H. & Hamed, H. N. Supervised, unsupervised, and semi-supervised feature selection: A review on gene selection. IEEE/ACM Trans. Comput. Biol. Bioinform. 13, 971–989. https://doi.org/10.1109/TCBB.2015.2478454 (2016).
22. Acharya, S., Cui, L. & Pan, Y. Multi-view feature selection for identifying gene markers: A diversified biological data driven approach. BMC Bioinform. 21, 483. https://doi.org/10.1186/s12859-020-03810-0 (2020).
23. Chen, S. et al. Analysis of Collagen type X alpha 1 (COL10A1) expression and prognostic significance in gastric cancer based on bioinformatics. Bioengineered 12, 127–137. https://doi.org/10.1080/21655979.2020.1864912 (2021).
24. Li, T. et al. TGF-beta-1/SOX9 axis-inducible COL10A1 promotes invasion and metastasis in gastric cancer via epithelial-to-mesenchymal transition. Cell Death Dis. 9, 849. https://doi.org/10.1038/s41419-018-0877-2 (2018).
25. Ding, X. et al. CTHRC1 promotes gastric cancer metastasis via HIF-1alpha/CXCR4 signaling pathway. Biomed. Pharmacother. 123, 109742. https://doi.org/10.1016/j.biopha.2019.109742 (2020).
26. Seeruttun, S. R. et al. CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes. Sci. Rep. 11, 19873. https://doi.org/10.1038/s41598-021-99321-w (2021).
27. Chen, Z. L., Qin, L., Peng, X. B., Hu, Y. & Liu, B. INHBA gene silencing inhibits gastric cancer cell migration and invasion by impeding activation of the TGF-beta signaling pathway. J. Cell. Physiol. 234, 18065–18074. https://doi.org/10.1002/jcp.28439 (2019).
28. Seeruttun, S. R. et al. Identification of molecular biomarkers for the diagnosis of gastric cancer and lymph-node metastasis. Gas- troenterol. Rep. (Oxf) 7, 57–66. https://doi.org/10.1093/gastro/goy023 (2019).
29. Zhang, H., Geng, Y., Sun, C. & Yu, J. Upregulation of ECT2 predicts adverse clinical outcomes and increases 5-Fluorouracil resistance in gastric cancer patients. J. Oncol. https://doi.org/10.1155/2021/2102890 (2021).
30. Gong, D. Y. et al. Upregulation of ECT2 is associated with transcriptional program of cancer stem cells and predicts poor clinical outcome in gastric cancer. Oncol. Lett. 20, 54. https://doi.org/10.3892/ol.2020.11915 (2020).
31. Sasahara, M. et al. Tissue RNF22 expression levels are associated with peritoneal recurrence and poor prognosis in gastric cancer. Anticancer Res. 41, 609–617. https://doi.org/10.21873/anticancer.14812 (2021).
32. Ambrosio, A. L., Fabbri, H. P. & De Pietro, S. M. Syntaxin 12 and COMMD3 are new factors that function with VPS33B in the biogenesis of platelet alpha-granules. Blood 130, 922–935. https://doi.org/10.1182/blood.2021010508 (2022).
33. Lee, Y. K. et al. Mitochondrial respiratory defect enhances hepatoma cell invasiveness via STAT3/NFE2L1/STX12 axis. Cancers (Basel) https://doi.org/10.3390/cancers12092032 (2020).

Acknowledgements

This study was supported by grants from the Key Research and Development Program of Shaanxi Province (2019NY-156), the Natural Science Foundation of Shaanxi Province (2020JM-692).

Author contributions

J.W. and Y.W. wrote the main manuscript text. J.S., Q.S. and J.X. performed the data analysis. H.W. and M.X. revised the text. Y.Z., L.W and Y.H. contributed to manuscript revision. All authors reviewed the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-21760-w.

Correspondence and requests for materials should be addressed to Y.W. or Y.Z.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.